BGB-3111 (zanubrutinib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BGB-3111 (zanubrutinib), covering 2022-03-08 to 2022-03-08. Get the full timeline:
Most recent: Clinical Trial Update: Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM) [Phase 2]